Dr Idbaih presents key results from Phase I study at ASCO 2018

In May 2018, Dr Ahmed Idbaih, GLIOTRAIN PI (ICM) presented at the American Society for Clinical Oncology (ASCO) 2018 meeting that took place in Chicago, IL. Dr Idbaih presented his talk entitled "Safety and preliminary efficacy data from a phase I study of an implantable low intensity pulsed ultrasound (LIPU) device for disrupting the blood-brain barrier (BBB) in patients treated by chemotherapy for recurrent glioblastoma (GBM)".

The BBB limits the efficacy of drug therapies for glioblastoma (GBM) and preclinical data indicate that low-intensity pulsed ultrasound can transiently disrupt the BBB and increase intracerebral drug concentrations. Preliminary results from this study, indicate that treatments were well tolerated and may increase the effectiveness of systemic drug therapies, such as carboplatin, in the brain without inducing neurotoxicity. You can read the recently published manuscript at this link.